Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Turner syndrome

Turner syndrome

Part of Heart Defects, Congenital

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Turner syndrome

8 trials tracked for Turner syndrome: 7 in phase 3 or 4 and 1 with published results. The most-cited published study has 36 citations.

8Trials tracked
7Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 5 Phase 3 2 Other / NA 1
  1. Phase 4 Predictive Markers in Growth Hormone Deficiency (GHD) and Turner Syndrome (TS) Children Treated With SAIZEN® Completed · 36 cited
  2. Phase 4 Long-Term Growth and Skeletal Effects of Early Growth Hormone Treatment in Turner Syndrome Completed
  3. Phase 4 Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism Completed
  4. Phase 4 First Year Growth Response Associated Genetic Markers Validation Phase IV Open-label Study in Growth Hormone Deficient and Turner Syndrome Pre-pubertal Children: the PREDICT Pharmacogenetics Validation Study Completed
  5. Phase 4 Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents Completed
  6. Phase 3 Study to Define Optimal IGF-1 Monitoring in Children Treated With NutropinAq Completed
Show 2 more trials
  1. Phase 3 Somatropin Treatment to Final Height in Turner Syndrome Completed
  2. N/A Effect of Growth Hormone on Early Brain Development in Girls With Turner Syndrome Completed

Showing the 8 most-cited and recently-updated of 8 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Turner syndrome: what the trials found

Several studies evaluated growth hormone and related therapies for pediatric growth. Saizen demonstrated significant improvements in IGF-1 SDS at month 1 (p<0.0001) 1. Somatropin showed statistically significant increases in Height Standard Deviation Score (SDS) from baseline to last measurement (p<0.001) 7, while also showing a reduction in height SDS after the attainment of final height (p<0.001) 7.

Additional investigations into growth interventions reported varying results for height metrics. One study noted significant changes in Height SDS and Height Velocity SDS at year 1 4. Clinical assessments of administration devices, such as the NutropinAq Pen, showed high rates of patient acceptance regarding handling 6. Furthermore, a study on Norditropin NordiFlex® evaluated ease of use across dose selection, modification, and injection 5.

Other treatments included 17 B estradiol, which was associated with changes in weight, BMI, and fat mass over 12 months 3. Humatrope was evaluated for its impact on mature height SDS and the age at which patients reached a bone age of 14.5 years 2.

Recent results — preliminary, needs further review

  • Somatropin (trial NCT01367834) is currently under investigation but results are not yet corroborated.

For the clinician treating this condition

  • Saizen significantly improves IGF-1 SDS at one month post-initiation 1.
  • Somatropin is associated with significant improvements in Height SDS from baseline to last measurement 7.
  • Clinical evaluations of delivery systems like the NutropinAq Pen and Norditropin NordiFlex® indicate high levels of ease of use for administration [5, 6].

AI synthesis of 7 cited trials, updated Jun 29, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
SHOX gene deficiency causes Langer mesomelic dysplasia with severe disproportionate short stature and limb hypoplasia
Genetics & Precision Medicine Sys. Review
SHOX gene deficiency causes Langer mesomelic dysplasia with severe disproportionate short stature and limb hypoplasia SHOX Gene Deficiency Linked to Specific Skeletal Growth Disorders
This narrative review explores the molecular basis of Langer mesomelic dysplasia caused by SHOX gene deficiency. The authors synthesize find…
A review of the SHOX gene shows how its deficiency leads to specific limb shortening and short stature in certain conditions.
Frontiers Aug 7, 2026
Multi-factor management models for thoracic aortic disease improve precision beyond diameter-only assessment
Cardiology Sys. Review
Multi-factor management models for thoracic aortic disease improve precision beyond diameter-only assessment New multi-factor model improves care for thoracic aortic disease
This mini-review synthesizes the management of thoracic aortic disease in young patients with various genetic and structural conditions. The…
Doctors are moving beyond just measuring artery size to look at genetics and lifestyle when managing heart risks in young patients.
Frontiers Jul 22, 2026
Early growth hormone initiation in Turner syndrome linked to higher final height in retrospective study
Diabetes & Endocrinology Cohort
Early growth hormone initiation in Turner syndrome linked to higher final height in retrospective study Starting Growth Hormone Earlier Could Add Inches to Adult Height
A retrospective cohort study of 31 Turner syndrome patients followed from 1996 to 2021 found that initiating growth hormone therapy at ≤6 ye…
A 25-year study confirms that starting treatment early is key for height, but it also reveals a dangerous drop-off in medical care as girls …
Frontiers Apr 10, 2026